RESUMEN

Introducción Se realizó un metaanálisis para evaluar el efecto de la mitomicina intravesical en comparación con la gemcitabina en el tratamiento del cáncer de vejiga sin invasión muscular. Métodos Se realizó una búsqueda bibliográfica sistemática hasta noviembre de 2021 y 6 estudios incluyeron 389 sujetos con cáncer de vejiga no invasivo al músculo al inicio del estudio; 197 de ellos recibieron mitomicina intravesical y 192 gemcitabina intravesical. Se informó de las relaciones sobre el efecto de la mitomicina intravesical en comparación con la gemcitabina en el tratamiento del cáncer de vejiga no invasivo al músculo. Se calculó la odds ratio (OR) con intervalos de confianza (IC) del 95% para evaluar el efecto de la mitomicina en comparación con el de la gemcitabina intravesical en el tratamiento del cáncer de vejiga no invasivo mediante el método dicotómico con un modelo de efectos aleatorios o fijos. Resultados La mitomicina intravesical obtuvo tasas significativamente mayores de recidiva (OR: 2,41; IC 95%: 1,43-4,08; p=0,001) y de cistitis química (OR: 4,39; IC 95%: 2,27-8,51; p<0,001) en comparación con la gemcitabina intravesical en sujetos con cáncer de vejiga no invasivo. Sin embargo, la mitomicina intravesical no mostró diferencias significativas en su efecto sobre la hematuria (OR: 1,71; IC 95%: 0,68-4,33; p=0,26), reacciones cutáneas (OR, 2,04; IC 95%: 0,59-7,07; p=0,26) y daños en la función hepática y renal (OR, 1,96; IC 95%; 0,35-10,96; p=0,44) en comparación con la gemcitabina intravesical en sujetos con cáncer de vejiga no invasivo al músculo. Conclusiones La mitomicina intravesical tuvo tasas de recidiva y cistitis química significativamente mayores y no hubo diferencias significativas en su efecto sobre la hematuria, la reacción cutánea y el daño de la función hepática y renal en comparación con la gemcitabina intravesical en sujetos con cáncer de vejiga no invasivo al músculo. Se necesitan más estudios para validar estos resultados (AU)

Introduction We performed a meta-analysis to evaluate the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. Methods A systematic literature search up to November 2021 was done and 6 studies included 389 subjects with non-muscle invasive bladder cancer at the start of the study; 197 of them were provided with intravesical-mitomycin and 192 with intravesical gemcitabine. The studies reported the relationships about the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. We calculated the odds ratio (OR) with 95% confidence intervals (CIs) to assess the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer using the dichotomous method with a random or fixed-effect model. Results Intravesical mitomycin had significantly higher recurrence rates (OR, 2.41; 95% CI, 1.43-4.08, P=.001) and chemical cystitis (OR, 4.39; 95% CI, 2.27-8.51, P<.001) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. However, intravesical mitomycin had no significant difference in its effect on hematuria (OR, 1.71; 95% CI, .68-4.33, P=.26), skin reaction (OR, 2.04; 95% CI, .59-7.07, P=.26), and liver and kidney functions damage (OR, 1.96; 95% CI, 0.35-10.96, P=.44) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. Conclusions Intravesical mitomycin had significantly higher recurrence rates and chemical cystitis and no significant difference in its effect on hematuria, skin reaction, and liver and kidney functions damage compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. Further studies are required to validate these findings (AU)

Asunto(s)

RESUMEN

INTRODUCTION: We performed a meta-analysis to evaluate the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. METHODS: A systematic literature search up to November 2021 was done and 6 studies included 389 subjects with non-muscle invasive bladder cancer at the start of the study; 197 of them were provided with intravesical-mitomycin and 192 with intravesical gemcitabine. The studies reported the relationships about the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. We calculated the odds ratio (OR) with 95% confidence intervals (CIs) to assess the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer using the dichotomous method with a random or fixed-effect model. RESULTS: Intravesical mitomycin had significantly higher recurrence rates (OR, 2.41; 95% CI, 1.43-4.08, p=0.001) and chemical cystitis (OR, 4.39; 95% CI, 2.27-8.51, p<0.001) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. However, intravesical mitomycin had no significant difference in its effect on hematuria (OR, 1.71; 95% CI, 0.68-4.33, p=0.26), skin reaction (OR, 2.04; 95% CI, 0.59-7.07, p=0.26), and liver and kidney functions damage (OR, 1.96; 95% CI, 0.35-10.96, p=0.44) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. CONCLUSIONS: Intravesical mitomycin had significantly higher recurrence rates and chemical cystitis and no significant difference in its effect on hematuria, skin reaction, and liver and kidney functions damage compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. Further studies are required to validate these findings.

Asunto(s)